BIOCON
₹274.00
-7.2 (-2.56%)
  • Advice
  • Hold
21 February, 2024 22:51 BSE: 532523 NSE: BIOCONISIN: INE376G01013

Start SIP in Biocon

Start SIP

Biocon Performance

Day Range

  • Low 273
  • High 284
₹ 274

52 Week Range

  • Low 192
  • High 307
₹ 274
  • Open Price282
  • Previous Close281
  • Volume5852991

Biocon Share Price

  • Over 1 Month 0.02%
  • Over 3 Month 17.24%
  • Over 6 Month 5.61%
  • Over 1 Year 20.63%

Biocon Key Statistics

P/E Ratio 27.4
PEG Ratio 0.1
Market Cap Cr 32,896
Price to Book Ratio 1.5
EPS -0.1
Dividend 0.5
Relative Strength Index 49.42
Money Flow Index 59.88
MACD Signal 3.32
Average True Range 11.92
Biocon Financials
IndicatorDec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 563519513507
Operating Expenses Qtr Cr 492452441551
Operating Profit Qtr Cr 716772-44
Depreciation Qtr Cr 31313029
Interest Qtr Cr 56554848
Tax Qtr Cr 9113-15
Net Profit Qtr Cr 2435471,811
IndicatorMar 2023
Total Revenue Annual Cr 2,264
Operating Expenses Annual Cr 1,969
Operating Profit Annual in Cr 24
Depreciation Cr 117
Interest Annual Cr 70
Tax Annual Cr 123
Net Profit Annual Cr 2,848
IndicatorMar 2023
Cash from Operating Activity Annual Cr 219
Cash from Investing Activity Annual Cr -1,178
Cash from Financing Annual Activity Cr 1,039
Net Cash Flow Annual Cr 81
IndicatorMar 2023
Total ShareHolders Funds Annual Cr 10,916
Fixed Assets Annual Cr 1,305
Total Non Current Assets Annual Cr 10,464
Total Current Assets Annual Cr 2,566
Total Assets Annual Cr 13,030
IndicatorMar 2023
Book Value Per Share Annual Rs 91
ROE Annual % 26
ROCE Annual % 1
Total Debt to Total Equity Annual -
EBDIT Annual Margin % 15
IndicatorDec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 3,5493,4623,4233,774
Operating Expenses Qtr Cr 3,0272,7212,7082,777
Operating Profit Qtr Cr 927742714997
Depreciation Qtr Cr 415389358364
Interest Qtr Cr 267248233249
Tax Qtr Cr 55423582
Net Profit Qtr Cr 660126101313
IndicatorMar 2023
Total Revenue Annual Cr 11,550
Operating Expenses Annual Cr 8,663
Operating Profit Annual in Cr 2,512
Depreciation Cr 1,113
Interest Annual Cr 419
Tax Annual Cr 254
Net Profit Annual Cr 463
IndicatorMar 2023
Cash from Operating Activity Annual Cr 1,853
Cash from Investing Activity Annual Cr -14,282
Cash from Financing Annual Activity Cr 13,049
Net Cash Flow Annual Cr 619
IndicatorMar 2023
Total ShareHolders Funds Annual Cr 17,867
Fixed Assets Annual Cr 20,649
Total Non Current Assets Annual Cr 39,709
Total Current Assets Annual Cr 12,334
Total Assets Annual Cr 52,043
IndicatorMar 2023
Book Value Per Share Annual Rs 187
ROE Annual % 3
ROCE Annual % 4
Total Debt to Total Equity Annual -
EBDIT Annual Margin % 26

Biocon Technicals

EMA & SMA

Current Price
₹274.00
-7.2 (-2.56%)
pointer
  • Bullish Moving Average
  • ___
  • 7
  • Bearish Moving Average
  • ___
  • 9
  • 20 Day
  • ₹276.65
  • 50 Day
  • ₹269.05
  • 100 Day
  • ₹261.60
  • 200 Day
  • ₹258.48
  • 20 Day
  • ₹275.04
  • 50 Day
  • ₹269.00
  • 100 Day
  • ₹254.17
  • 200 Day
  • ₹254.33

Biocon Resistance and Support

PIVOT
₹276.82
Resistance
First Resistance 280.98
Second Resistance 287.97
Third Resistance 292.13
RSI 49.42
MFI 59.88
MACD Single Line 3.32
MACD 3.04
Support
First Resistance 269.83
Second Resistance 265.67
Third Resistance 258.68

Biocon Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 6,233,749 231,147,413 37.08
Week 12,943,394 487,836,535 37.69
1 Month 9,115,794 368,733,852 40.45
6 Month 4,943,755 212,878,070 43.06

Biocon Result Highlights

Biocon Synopsis

NSE-Medical-Biomed/Biotech

Biocon is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1992.90 Cr. and Equity Capital is Rs. 600.30 Cr. for the Year ended 31/03/2023. Biocon Ltd. is a Public Limited Listed company incorporated on 29/11/1978 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L24234KA1978PLC003417 and registration number is 003417.
Market Cap 32,846
Sales 2,101
Shares in Float 46.82
No of funds 257
Yield 0.53
Book Value 3.09
U/D Vol ratio 2.2
LTDebt / Equity 12
Alpha -0.04
Beta 1.17

Biocon

Owner NameDec-23Sep-23Jun-23Mar-23
Promoters 60.64%60.64%60.64%60.64%
Mutual Funds 9.31%8.26%7.47%7.19%
Insurance Companies 5.12%5.76%5.09%4.68%
Foreign Portfolio Investors 6.55%7.97%9.52%10.2%
Financial Institutions/ Banks
Individual Investors 14.47%13.61%13.34%13.2%
Others 3.91%3.76%3.94%4.09%

Biocon Management

Name Designation
Ms. Kiran Mazumdar Shaw Executive Chairperson
Mr. Siddharth Mittal Managing Director & CEO
Prof. Ravi Rasendra Mazumdar Non Exe.Non Ind.Director
Mr. Eric Vivek Mazumdar Non Exe.Non Ind.Director
Mr. Meleveetil Damodaran Lead Independent Director
Dr. Vijay Kumar Kuchroo Independent Director
Mr. Bobby Kanubhai Parikh Independent Director
Mr. Peter John Bains Independent Director
Mr. Naina Lal Kidwai Independent Director

Biocon Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Biocon Corporate Action

Date Purpose Remarks
2024-02-08 Quarterly Results
2023-11-10 Quarterly Results
2023-08-10 Quarterly Results
2023-05-23 Audited Results & Final Dividend
2023-04-26 Others To consider, Fund Raising. per share(20%)Final Dividend (Rs.0.5000 per share(10%)Final Dividend (Post Bonus Issue))
Date Purpose Remarks
2023-07-07 FINAL Rs.1.50 per share(30%)Final Dividend
2022-07-01 FINAL Rs.0.50 per share(10%)Final Dividend

About Biocon

Biocon limited is a biopharmaceutical company in India and it is Asia's largest biotechnology company. The company was founded by Kiran Mazumdar-Shaw in 1978 and is headquartered in Bangalore, India. The company has more than 13,500  employees. It focuses on all phases of the product cycle from researching to development and then introducing them to the market.  They mainly concentrate on the research and development of advanced therapies for the treatment of cancer, diabetes, and autoimmune disease. The company's medicines are helping the lives of patients in more than 120 countries by providing access to all their medicines and therapies. 

Some of Biocon's important brands in India are INSUGEN (rh-insulin), BIOMAb EGFR (Nimotuzumab), CANMAb (Trastuzumab),KRABEVA (Bevacizumab), ALZUMAb(Itolizumab), BLISTO (Glimepiride + Metformin), BASALOG (Glargine), etc. 

Biocon FAQs

What is Share Price of Biocon ?

Biocon share price is ₹274 As on 21 February, 2024 | 22:37

What is the Market Cap of Biocon ?

The Market Cap of Biocon is ₹32896.4 Cr As on 21 February, 2024 | 22:37

What is the P/E ratio of Biocon ?

The P/E ratio of Biocon is 27.4 As on 21 February, 2024 | 22:37

What is the PB ratio of Biocon ?

The PB ratio of Biocon is 1.5 As on 21 February, 2024 | 22:37

Is it a good time to invest in Biocon Limited?

Biocon has an operating revenue of Rs.7,290.70 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 16% is great. However, analysts are of mixed views on the stock.

How many times has Biocon Limited given dividends since 2004?

Biocon Ltd. has declared 17 dividends since July 1, 2004.

What is the stock price CAGR of Biocon Limited?

The stock price CAGR of Biocon Limited for 10 Years is 24%, 5 Years is 17%, 3 Years is 5%, 1 Year is -21%.

What is the debt-to-equity ratio of Biocon Limited?

The debt-to-equity ratio of Biocon Limited is 39% which signals a healthy balance sheet.

What is the ROE of the Biocon Limited?

The ROE of Biocon Limited is 9% which is fair but needs improvement.

Who is the Managing Director of Biocon Limited?

Mr. Siddharth Mittal is the Managing Director and CEO of Biocon Limited.

Is Biocon a good stock to buy?

According to the record analysis of moneyworks4me, Biocom limited is an average quality company. 

How to buy shares of Biocon Ltd?

The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

What people are saying about us!

Raja Mohan Challa Raja Mohan Challa

Great app, you will have very good understanding of fundamental and technical analysis if you look into detail, Which will help you to invest and timing. Thanks

Ravi K Tiwari Ravi K Tiwari

New avtaar is quite progressive, better than before.

santosh kashyap santosh kashyap

Superb app which has daily recommendations also..

Uttam Kumar Sangam Uttam Kumar Sangam

good investing app

Sultan Shaikh Sultan Shaikh

excellent app and service

Q2FY23